WT1-guided pre-emptive therapy after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia

• Published in: International journal of hematology Vol. 120; no. 3; pp. 337 - 346
• Main Authors: Arai, Shota, Tachibana, Takayoshi, Izumi, Akihiko, Takeda, Takaaki, Tamai, Yotaro, Sato, Shuku, Hashimoto, Chizuko, Fujimaki, Katsumichi, Ishii, Ryuji, Kabasawa, Noriyuki, Hirasawa, Akira, Inoue, Yasuyuki, Tanaka, Masatsugu, Suzuki, Takahiro, Nakajima, Hideaki
• Format: Journal Article
• Language: English
• Published: Singapore Springer Nature Singapore 01.09.2024; Springer Nature B.V
• Subjects: Acute myeloid leukemia; Adolescent; Adult; Aged; Allografts; Chemotherapy; Cytarabine; Female; Hematology; Hematopoietic Stem Cell Transplantation; Hematopoietic stem cells; Humans; Leukemia; Leukemia, Myeloid, Acute - therapy; Male; Medicine; Medicine & Public Health; Middle Aged; mRNA; Neoplasm, Residual; Oncology; Original Article; Retrospective Studies; Stem cell transplantation; Stem cells; Survival; Transplantation; Transplantation, Homologous; WT1 Proteins - genetics; Young Adult; Pre-emptive therapy; Acute myeloblastic leukemia; Disease relapse; WT1

Measurable residual disease (MRD)-guided pre-emptive therapies are now widely used to prevent post-transplant hematological relapse in patients with acute myeloid leukemia (AML). This single-center retrospective study aimed to clarify the significance of pre-emptive treatment based on Wilms’ tumor g...